RED HOT Contributors


ResMed Shares dip on Q3 release despite meeting EPS expectations



ResMed (NYSE:RMD) saw shares fall today in after hours trading after the medical device maker posted 3rd quarter earnings that met earnings per share expectations, but fell short on revenue.

The San Diego-based company posted profits of $87.8 million, or 62¢ per share, on sales of $514.2 million for the 3 months ended March 31, for negative bottom-line growth of 3.3% while sales grew 13.3% compared with the same period in the previous year.

Adjusted to exclude 1-time items, earnings per share were 71¢, just in line with expectations on The Street, where analysts were expecting to see sales of $519.9 million.

“We had solid double-digit constant currency revenue growth in Q3, led by our Brightree software solutions as well as mask and device sales. This quarter we saw strong demand for our new AirFit 20 range of masks. We also made significant progress on software innovation with the launch of enhanced integration capabilities with Brightree and our AirSolutions cloud-based software platform.  In our current quarter, we are launching our latest market-leading innovation: the ResMed AirMini – the world’s smallest CPAP. Our focus on changing 20 million lives by 2020 has driven a pipeline of new products and connected care solutions that improve patient outcomes, create efficiencies for our homecare customers, and help physicians and providers better manage chronic disease while lowering healthcare costs,” CEO Mick Farrell said in a press release.

ResMed shares have dropped 6.5% in after hours trading, down $4.75 to trade at $68.10 as of 4:4o p.m. EDT.


We Support OUR Contributors

Get Our Newsletter

 Receive podcast updates
Exclusive insights
Patient Engagement Tips from industry experts
We hate SPAM as much as you do and promise to keep your email address safe.
  • Subscribe to the Podcast